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fhis review is a sequel to our previous reports highlighting
he most important recent literature in single-photon emis-
ion computed tomography (SPECT) myocardial perfusion
maging, cardiac positron emission tomography (PET),
ardiac computed tomography (CT), and cardiac magnetic
esonance imaging (MRI). In almost all cases, these studies
ere published in the English-language literature between
pril 1, 2005, and March 31, 2006. The explosion of
iterature on cardiac CT has led us to add another author,
ric E. Williamson, who has particular expertise in that
rea. The decision to arbitrarily include some articles and
xclude others has become even more difficult. We once
gain apologize to those whose work we have excluded or
nadvertently overlooked. We can assure both authors and
eaders that we have done our best to ignore any personal
iases in reaching these decisions. We continue to believe
hat the optimal application of imaging to clinical problems
equires careful assessment across imaging modalities (i.e.,
hinking outside the “silos” in which most imagers work).
e have therefore again organized this summary around
opical themes in an effort to encourage a broad approach.
ECHNICAL ADVANCES
PECT. Although SPECT myocardial perfusion imaging
s a relatively mature technique, there continue to be
mportant technical advances. Leslie et al. examined the
otential value of stress lung-to-heart ratio in 718 patients
ndergoing sestamibi SPECT imaging (1). Similar to pre-
ious studies evaluating this ratio using thallium imaging,
his ratio provided important prognostic information inde-
endent of other clinical, stress, and perfusion variables.
omewhat surprisingly, in this series it appeared more
mportant than the summed stress score.
Several studies added to our understanding of attenuation
orrection. Masood et al. (2) published multi-center results
sing CT-based attenuation correction of SPECT imaging
rom a multi-center study. The major benefit of attenuation
orrection was an improved normalcy rate. The degree of
enefit in sensitivity, specificity, and accuracy varied among
eaders. Fricke et al. (3) compared CT-based attenuation
orrection of SPECT with nitrogen-13 ammonia in 23
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f Medicine, and †Department of Radiology, Mayo Clinic and Mayo Foundation,
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esting.
Manuscript received May 26, 2006; accepted June 8, 2006.atients. Attenuation correction improved the concordance
etween SPECT and PET studies in the inferior wall, but
ifferences between SPECT and PET persisted in the apex
nd anterolateral wall.
Hesse et al. (4) published procedural guidelines for
yocardial perfusion imaging on behalf of the European
ssociation of Nuclear Medicine and the European Society
f Cardiology. The sections of that document describing
uality control and reconstruction methods, as well as
ttenuation and scatter compensation, are of particular value
o the practicing clinician.
ET. Johnson et al. (5) quantified the heterogeneity of
ubidium PET perfusion using a detailed Marcovian homo-
eneity analysis. Patchy resting perfusion predicted mild
tress-induced defects; the authors suggested that these
ndings may reflect coronary microvascular dysfunction.
T. Technical advances in CT continue to be very rapid,
ith development of a new generation of multi-detector-
ow CT scanners approximately every 2 years. In 2005, the
rst publications regarding the capabilities of the 64-
etector-row CT systems appeared. Interestingly, the dif-
erent CT vendors branched out into different directions.
ncreasing the number of detector rows remains a priority in
evelopment, but how this increase is applied differs con-
iderably among the new systems. Kondo et al. (6) reported
heir initial experience performing non-electrocardiogram
ECG)-gated volumetric cardiac imaging using a 256-
etector-row CT. Although temporal resolution of this
ystem is limited, the greatly increased coverage region,
mproved spatial resolution, and elimination of ECG-gating
rtifacts show promise for future cardiac applications. Flohr
t al. (7) published the first evaluation of a dual-source CT
ystem using 2 X-ray tubes and corresponding detector
rrays mounted on a single gantry offset from each other by
0°. This system offers superior temporal resolution (83 ms)
ompared with current 64-row systems, with obvious ben-
fits of improved functional assessment and decreased
otion-related artifacts.
RI. Several recent advances in MRI have involved tissue
roperties. Wen et al. (8) applied a combination of in vivo
RI displacement and velocity measurements to calculate
egional myocardial stiffness and compared their results to
x vivo strain gauge measurements in dogs. Magnetic
esonance imaging–based temperature mapping has been
ossible since the early 1990s, but improved scanner per-
ormance has increased interest in using this technique.
everal investigators used MRI temperature mapping in
o
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December 5, 2006:2324–39 Year in Cardiac Imagingrgans such as the liver (9), esophagus (10), and prostate
11). It remains to be seen whether similar techniques could
e applied to the heart.
Although MRI has not witnessed the complete redevel-
pment of scanner hardware that is occurring with CT, one
rea of potential revolutionary advancement is interven-
ional MRI. The interventional MRI literature remains very
reliminary although promising. Under MRI guidance,
repally et al. (12) guided catheters across the interatrial
eptum in 5 pigs (Fig. 1). Krombach et al. (13) performed
ntramyocardial injection of contrast into 7 pigs. Raval et al.
14) performed coarctation stenting in 13 pigs. Wider
pplication of this technology will require MRI-compatible
atheters and better tracking systems.
IABILITY
hareonthaitawee et al. (15) published a comprehensive review
f the available evidence regarding revascularization in patients
ith left ventricular (LV) systolic dysfunction, which high-
ighted the deficiencies of the existing literature and placed
iability studies in an appropriate clinical context.
ET. Several studies attempted to define the role of PET
iability studies in revascularization decisions. Stankewitz et
l. (16) compared rubidium perfusion defect severity and
ashout with fluorodeoxyglucose (FDG)-perfusion mis-
atch in 194 patients and found that perfusion imaging
lone could not identify viability defined by FDG-perfusion
igure 1. Interventional magnetic resonance imaging (MRI). (A) MRI
-chamber view shows a wire (arrowhead) that has been passed into the left
trium (LA) through the fossa ovalis. RA right atrium. (B) MRI short-axis
iew better shows the catheter (black arrowheads) passing through the fossa
valis (white arrow). (C) Injection of contrast material through the catheter
roduces an MR angiogram in which the left-side chambers and aorta but not
he right-side chambers are visualized. (D) Gross pathologic photograph of the
ossa ovalis viewed from the left atrial side shows the site of septal puncture
black arrow). Modified from Arepally et al. (12).ismatch. Desideri et al. (17) performed PET viability
F
essessment with ammonia and FDG in 261 patients with
schemic cardiomyopathy. Patients who were revascularized
ad better outcomes than those patients who were treated
edically. In the medically treated patients, the extent of
ismatch was a predictor of adverse outcomes, but only if it
xceeded 20% of the left ventricle. In contrast, Sawada et al.
18) performed PET viability assessment in 61 patients with
iabetes and ischemic LV dysfunction and reported that
ismatch of a much smaller 3% of the left ventricle
dentified patients whose survival was poorer with medical
herapy.
Slart et al. (19) reported that a threshold of 50% or
reater for FDG uptake predicted improvement in segmen-
al function after revascularization in 38 patients. In a
econd paper, Slart et al. (20) reported in 47 patients that
ual-isotope simultaneous SPECT acquisition with sesta-
ibi and FDG predicted post-revascularization improve-
ent just as well as ammonia-FDG PET.
Tarakji et al. (21) described a large series of 765 patients
ho underwent comprehensive PET imaging assessment of
oth viability and stress-induced ischemia (Fig. 2). In a
arefully performed propensity analysis, early revasculariza-
ion was associated with a significantly better survival. In an
ccompanying editorial, Gibbons et al. (22) highlighted the
trengths and weaknesses of this very large study.
T. Two CT methods have been used to detect infarcted
yocardium. The first is decreased myocardial perfusion
uring the first pass of contrast material. The second is
ecreased washout of contrast material on delayed images,
alled “delayed enhancement” or “delayed hyperenhance-
ent,” similar to the technique used with MRI.
Although both methods were first reported over 20 years
go, CT is still at an early stage in its assessment of viability;
he literature to date consists of animal studies or very small
uman trials (23) (Fig. 3). Last year, 4 small studies
nvestigated the potential of myocardial viability assessment
sing contrast-enhanced CT (23–26) (Table 1). Although
RI can provide the same information without radiation,
mportant viability information is potentially available from
ardiac CT for patients undergoing CT for other reasons.
igure 2. Mortality for patients treated medically (no intervention) and
atients undergoing early intervention, using propensity-matched groups.
rom Tarakji et al. (21). FDG  fluorodeoxyglucose; PET  positron
mission tomography.
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Year in Cardiac Imaging December 5, 2006:2324–39RI. Delayed enhancement by MRI has been extensively
alidated and is frequently used as a reference standard for
yocardial infarction (MI). Slomka et al. (27) used MRI
elayed enhancement to validate a SPECT myocardial
nfarct quantification tool, a reversal from previous years
hen nuclear methods were used to validate MRI. In 29
atients with chronic ischemic cardiomyopathy, Kuhl et al.
28) showed that MRI delayed enhancement predicted
ecovery of function as well as 18F-FDG PET.
Several other studies attempted to combine delayed
nhancement with other MRI parameters to make a com-
rehensive evaluation of viability. Bodi et al. (29) examined
0 patients with ST-segment elevation myocardial infarc-
ion (STEMI). Using a combination of 4 MRI-measured
ndexes, including delayed enhancement, they developed a
coring system that predicted recovery of regional function 6
onths later (Fig. 4).
Although delayed enhancement indicates tissue damage,
t is not specific for infarction. Knappen et al. (30) measured
elayed enhancement with MRI and blood flow with PET.
n 12 patients with chronic MI, blood flow was decreased in
reas of delayed enhancement, but in 21 patients with
ypertrophic cardiomyopathy, blood flow was slightly in-
reased in areas of delayed enhancement. Thus, delayed
nhancement due to MI seems to represent a different form
f tissue damage than delayed enhancement due to hyper-
rophic cardiomyopathy.
Hunold et al. (31) showed that other disease states
ausing delayed enhancement can be distinguished from
nfarction by the distribution of the enhancement (Fig.
). All 391 patients with known infarction had delayed
nhancement in a vascular distribution (i.e., it proceeded
rom the endocardial to epicardial border and was con-
ned to vascular territories). Nineteen patients had other
yocardial diseases (including myocarditis and sarcoid-
sis), no history of MI, and normal coronary arteries at
ardiac catheterization. Although these patients also
howed delayed enhancement, it was in a nonvascular
igure 3. Contrast-enhanced cardiac computed tomography (CT) (A) and
elayed-enhancement magnetic resonance imaging (MRI) (B) of a chronic
yocardial infarction. The CT image shows first pass hypoenhancement in
he left ventricular apex and anterior wall. The MRI shows a corresponding
rea of delayed hyperenhancement, consistent with prior myocardial
nfarction. LA  left atrium; LV  left ventricle; RA  right atrium; RV
right ventricle. From Nikolaou et al. (23).istribution. Ta
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iagnosis. SPECT. Patients with previous radiation therapy
or breast and chest cancer are increasingly studied by SPECT.
n the oncology literature, Marks et al. (32) prospectively
tudied 114 patients after radiation therapy for left-side breast
ancer by SPECT. New perfusion defects appeared in 42% of
he patients within 2 years and were more common in patients
ith more than 5% of their left ventricle included within the
adiation therapy field.
igure 4. Percentage of segments with normal wall motion (WM) at 6 months (w
all thickness5.5 mm, normal perfusion, wall thickening during low-dose dobut
m and/or normal perfusion should be present.   index absent;   index p
igure 5. Distribution of delayed enhancement. (A) Four-chamber, (B)
esonance imaging (MRI) delayed-enhancement images in a patient w
nhancement (black arrows) in the anterior wall from apex to mid ventric
istribution and proceeds from endocardial to epicardial, which is expect
atient with known sarcoidosis and normal coronary arteries. The delayed enhanc
he enhancement does not proceed from endocardial to epicardial but actuallyThe relationship between perfusion defects and ECG evi-
ence of ischemia is not fully defined. Weinstaft et al. (33)
arefully compared inducible ST-segment depression and re-
ersible perfusion defects in 129 patients undergoing SPECT.
he ST-segment depression correlated with defect size and
everity in those patients with contiguous ischemia but not in
hose patients with anatomically opposed ischemia.
ET. The diagnostic use of PET imaging is increasing.
ateman et al. (34) compared PET rubidium-82 imaging in
kening2 mm) depending on the 5-level comprehensive score. Viability indexes:
2 mm, and transmural extent of necrosis50%. In level 2, wall thickness5.5
; /  index may be present or absent. From Bodi et al. (29).
mber, (C) midventricular short-axis, and (D) apical short-axis magnetic
anterior wall infarct. The MRI images show subendocardial delayed
e enhancement is confined to the left anterior descending coronary artery
myocardial infarction. (E) Four-chamber and (F) short-axis images in aall thic2-cha
ith an
le. Th
ed inement (white arrows) is patchy and not confined to a vascular distribution.
spares the endocardium. Modified from Hunold et al. (31).
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Year in Cardiac Imaging December 5, 2006:2324–3912 patients with 112 SPECT controls. In those matched
harmacologic stress patients with a mean body mass index
f 32, PET had superior diagnostic accuracy. In a com-
rehensive editorial, Di Carli et al. (35) outlined the need
or clinical outcomes data to better establish the correct role
f PET. Chow et al. (36) compared exercise and dipyri-
amole stress in patients studied with ammonia-13. Perfu-
ion defects were larger with exercise, suggesting that it is
he preferred stress technique.
In a mechanistic study, Brunken et al. (37) assessed
yocardial perfusion reserve using nitrogen-13 ammonia
ET imaging in 14 patients with cyanotic congenital heart
isease and carefully compared them to 10 healthy controls.
lthough myocardial perfusion reserve was diminished in
he patients with congenital heart disease, this primarily
eflected higher perfusion in the basal state which preserved
xygen delivery to the myocardium. At hyperemic stress,
erfusion measurements and coronary vascular resistances
ere similar to those of normal subjects.
T CORONARY ANGIOGRAPHY. The most recent generation
f scanner, the 64-detector-row CT, represents an improve-
ent over the 16-detector-row systems evaluated previously
igure 6. Multiple volume rendered, curved multiplanar (cMPR), and max
omography (CT) angiogram with a corresponding image from a conv
oncalcified atheroma in the proximal-mid left anterior descending corona
oronary angiogram. Images provided by N. R. A. Mollet and P. de FeytFig. 6). Table 2 lists the prospective 64-detector studies 3hat compare coronary CT angiography (CTA) to cardiac
atheterization for the detection of coronary stenosis (38–
4). The main benefits realized by the 64-detector systems
re in the number and size of coronary segments that are
onsidered analyzable. Of the 64-detector studies listed this
ear, nearly one-half (3 of 7) analyzed all segments com-
ared with less than one-third (3 of 10) of the 16-detector
tudies reviewed last year. Four of the seven 64-detector
tudies evaluated this year did not exclude any vessels on the
asis of size. In spite of these improvements, low heart rates
re required to limit motion artifacts. Therefore, patients
till receive beta-blockers before imaging and heart rates in
he studies remain in the 50s and low 60s (beats/min).
alcium remains a source of false positive results; Mollet et
l. (38) and Raff et al. (43) published separate studies
howing that specificity decreases with increasing calcium.
RI. Myocardial perfusion is the most extensively validated
ethod of detecting CAD with MRI. Although these
tudies date back to the early 1990s, there are numerous
ays to analyze the images, with little standardization
etween studies. Redrigues de Avila et al. (45) compared
ifferent semiquantitative measures of perfusion reserve in
intensity projection (MIP) reformatted images from a coronary computed
al angiogram (CA). The CT images demonstrate mixed calcified and
ery causing focal significant stenosis, as demonstrated on the conventional
tterdam, the Netherlands.imum
ention7 patients with known CAD. Using cardiac catheterization
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December 5, 2006:2324–39 Year in Cardiac Imagings the reference standard, they found that signal intensity
pslope was the best parameter for distinguishing different
egrees of stenosis. Using deconvolution of signal intensity
urves, Selvanayagam et al. (46) provided evidence that
esting myocardial blood flow is decreased in hibernating
egments.
One limitation of MRI perfusion is the frequent presence
f a dark rim-like artifact that can be mistaken for a
erfusion defect. Some have suggested that the rim is caused
y high local concentrations of contrast material (a well
nown phenomenon in MRI). Others have suggested that
he rim is caused by motion or by limits in spatial resolution.
i Bella et al. (47) studied explanted canine hearts and
oncluded that the main cause of the artifact was limited
patial resolution.
Several centers have attempted to use MRI for direct
oronary visualization. Sakuma et al. (48) studied 39 pa-
ients with a coronary MRI sequence that corrected for
atient respiration. In the subset of 20 patients who under-
ent cardiac catheterization they reported a (per patient)
ensitivity and specificity of 83% and 75%, respectively.
laque characterization. CT. Computed tomography has
he potential to provide a noninvasive means of character-
zing coronary plaque. Evaluation of the vessel wall using
he cross-sectional capability of CT could theoretically
istinguish “vulnerable plaques” from those that are less so.
ntil recently, few data were available; however, 3 studies
ere published in the past year evaluating the ability of CT
o characterize noncalcified atherosclerotic plaques.
Carrascosa et al. (49) compared coronary CTA to intra-
ascular ultrasound (IVUS) for the characterization of
alcified and noncalcified coronary plaque in 40 patients
ith known CAD. They studied 276 coronary plaques
sing a 4-detector row system and found perfect discrimi-
ation between calcified and noncalcified plaques (receiver
perating characteristic [ROC] area  1.00) and good
iscrimination between fibrous and soft plaques (ROC area
0.82), using 185 Hounsfield units (HU) and 88 HU as
he respective cutoff values. Interobserver variability was not
tudied.
Ferencik et al. (50) evaluated the interobserver reproduc-
bility of coronary plaque detection in 45 patients using
6-detector coronary CTA. They evaluated 735 coronary
egments, excluding 50 for motion artifact or insufficient
aliber (patients with a heart rate of 65 beats/min were
xcluded). High interobserver agreement was reported for
oth calcified (97.7% agreement; kappa  0.93) and non-
alcified plaque (92.4%; kappa  0.82). Plaque volume was
ot quantified.
Leber et al. (51) compared 64-detector-row CTA to
VUS for the detection and characterization of noncalcified
therosclerotic plaque in 38 nonstenosed coronary arteries
rom 20 patients. Although CT systematically overesti-
ated volumes of calcified plaque and underestimatednoncalcified and mixed plaque volumes, there was a goodTa
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Year in Cardiac Imaging December 5, 2006:2324–39verall correlation of plaque volumes between CTA and
VUS (r2  0.69). Unfortunately, interobserver variability
or CT plaque volume measurements was high (37%).
RI. Because the coronary arteries are too small and fast-
oving to be reliably imaged with MRI, plaque character-
zation studies have focused on larger, more stationary
essels such as the carotid arteries. In 21 patients scheduled
or carotid endarterectomy, Cai et al. (52) performed pre-
ndarterectomy in vivo MRI for carotid plaque character-
zation and compared it with postoperative histology. They
ound good correlation of measurements of the length (r 
.73; p  0.001) and area (r  0.80; p  0.001) of the
laques’ fibrous caps and of the area of the necrotic core
r  0.87; p  0.001).
Saam et al. (53) reported good interobserver variability of
arotid plaque measurements. They measured 16 different
ariables, including wall and lumen volume. Their intraclass
orrelation coefficient was0.90 for all their measurements.
rom their data, they calculated that a study of 43 patients
ould have adequate (80%) power to show a 5% change in
of their measurements (wall/outer wall ratio and wall
olume) and a 10% change in a third measurement (per-
entage of lipid-rich necrotic core of the plaque).
rognosis. SPECT. The potential prognostic value of the
ymptom of dyspnea has not been well defined. Abidov et
l. (54) reported on 17,991 patients undergoing stress
PECT imaging. Dyspnea was associated with an increased
isk of death in patients with and without a known history
f CAD, after adjustment for all other significant factors
igure 7. Probability of survival free of cardiac death for 12,279 patients wi
maging parameters. From Abidov et al. (54).Fig. 7). In an accompanying editorial, Marwick (55) eutlined the uncertainty regarding the pathophysiologic
echanism responsible for this finding but suggested isch-
mia, LV dysfunction, and obesity as possibilities.
Shaw et al. (56) compared the prognostic value of stress
PECT imaging in 1,993 African Americans, 464 Hispanics,
nd 5,258 Caucasian non-Hispanic patients (Fig. 8). African
merican and Hispanic patients had worse baseline clinical
arameters, more abnormal SPECT scans, and worse out-
omes, even after adjustment for baseline inequalities.
In 1,367 selected patients, Navare et al. (57) showed the
rognostic value of dobutamine stress SPECT, as well as
he importance of the stress ECG and heart rate response in
mage interpretation.
Dakik et al. (58) demonstrated the prognostic value of
denosine SPECT imaging in 126 stable patients early after
cute myocardial infarction. Acampa et al. (59) reported that
vent-free survival was better in 196 patients with negative
PECT studies after a myocardial infarction compared with
hose with negative dobutamine echocardiograms.
Three studies reported on the prognostic value of stress
PECT imaging in the elderly. Valeti et al. (60) examined
47 patients aged 75 years; SPECT classified most
atients as low risk or high risk and performed considerably
etter than the Duke treadmill score. De Winter et al. (61)
emonstrated the incremental prognostic value of gated
PECT LV functional data in 294 patients aged75 years.
afrir et al. (62) demonstrated the prognostic value of LV
ilatation and myocardial ischemia assessed by SPECT in
62 patients aged 80 years.
Additional studies of diabetic patients continue to
known coronary artery disease, adjusted for multiple clinical and perfusionmerge. Elhendy et al. (63) reported that reversible perfu-
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December 5, 2006:2324–39 Year in Cardiac Imagingion defects and summed stress score were independently
redictive of all-cause mortality and hard cardiac events in
97 diabetic patients. Valensi et al. (64) recruited 370
symptomatic diabetic patients with at least 2 additional risk
actors for SPECT imaging. Silent myocardial ischemia
etected by SPECT predicted major cardiac events for the
atients60 years of age but not for those60 years of age.
e Feuvre et al. (65) performed stress SPECT in 100
igh-risk diabetic patients and dobutamine echocardiogra-
hy in 75 of these patients. Silent myocardial ischemia was
ore frequently detected by SPECT and led to coronary
evascularization in 15 patients (65).
ET. Previous studies have reported a considerable cardiac
vent rate in patients with vasodilator-induced ST-segment
epression despite normal SPECT images. Chow et al. (66)
ollowed 72 patients with dipyridamole-induced ischemic
CG changes but normal perfusion by rubidium PET for
ore than 2 years. There were no cardiac deaths and only 1
onfatal MI, suggesting that those patients had an excellent
rognosis, in contrast to the previous reports using SPECT.
Schindler et al. (67) employed nitrogen-13 ammonia
ET imaging to detect perfusion abnormalities in response
o sympathetic stimulation with cold pressor testing. Im-
aired blood flow increases were associated with a higher
ncidence of subsequent cardiovascular events.
T: CORONARY CALCIUM SCANNING. Four prospective
tudies correlating the presence and/or quantity of coro-
ary calcium with outcomes in asymptomatic patients
ere published in the past year (68 –71) (Fig. 9, Table 3).
espite a modest number of total cardiovascular events
nd incomplete measurement of risk factors, these studies
onfirm the incremental prognostic value of coronary
alcium quantification compared with conventional risk
igure 8. Estimated annual death rates for different patient groups accordi
etween African American, Hispanic, and Caucasian non-Hispanic patien
eart disease. *Not reported. From Shaw et al. (56).ng to the summed stress score risk group on perfusion imaging. The differences
ts were highly significant (p  0.0001). CV  cardiovascular; IHD  ischemicactor assessment.
e
aigure 9. Survival curves demonstrating the association between initial
alcium score categories and survival free from new coronary heart disease
vents (A) and total new cardiovascular disease events (B), adjusted for age
nd gender differences. From Vliegenthart et al. (69).
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Year in Cardiac Imaging December 5, 2006:2324–39RI. Previous animal studies have shown that with severe
schemia myocytes and capillaries may be damaged to a
egree that contrast cannot enter the infarct (72) to cause
elayed enhancement by MRI. In these cases the infarct
ay have an enhancing rim of tissue surrounding a nonen-
ancing core. The presence of a central nonenhancing core
as been attributed to “microvascular obstruction” and also
inked with prognosis in 1 previous small study (73).
Hombach et al. (74) examined 110 patients within a week
f an acute MI. All patients were classified as having infarcts
ith or without a nonenhancing core (called “persistent
icrovascular obstruction”). During follow up of 225  92
ays, 16 of the patients had a “major cardiac event,” which
as defined as death, MI, or a variety of soft events,
ncluding revascularization. The presence of microvascular
bstruction at baseline MRI was associated with cardiac
vents (p  0.04) and decreased “event-free survival” (p 
.04). However, microvascular obstruction was also associ-
ted with larger infarcts; with only 16 events, most of which
ere soft, the authors were unable to control for infarct size
nd other confounding variables.
The presence of delayed enhancement itself is clinically
mportant. Nazarian et al. (75) performed MRI on 26
atients referred for electrophysiologic (EP) study. Al-
hough only 5 of their 26 patients had inducible tachycardia,
he presence of delayed enhancement involving 26% to 50%
r 51% to 75% wall thickness was predictive of inducible
entricular tachycardia at EP study (p  0.001).
ENTRICULAR FUNCTION
T. As we described last year, previous studies have
emonstrated the ability of 16-detector-row systems to
ccurately calculate LV ejection fraction (LVEF). There
ere 2 notable additions this year. Salm et al. (76) showed
ood correlation between 16-detector-row coronary CTA
nd both echocardiography (kappa  0.78) and MRI
kappa  0.86) for the assessment of LV regional wall
otion in 25 patients. Coche et al. (77) demonstrated
imilar correlation between ECG-gated pulmonary arterial
TA and radionuclide ventriculography for both LVEF
r  0.91) and right ventricular ejection fraction (RVEF)
r  0.89).
RI. Magnetic resonance imaging volume measurements
re highly reproducible and are becoming a reference
tandard. Recent studies focusing on normal values or
efinements of the measurements reflect the maturity of this
iterature. Hudsmith et al. (78) published normal values for
V, RV, and atrial measurements based on 108 subjects
Table 4). This study also demonstrated the reproducibility
f MRI volume measurements with excellent intraobserver
nd interobserver variability of LV measurements. In 111
ormal subjects, Sievers et al. (79) determined normal values
f left atrial measurements.
Currently, the acquisition of functional images requiresmultiple breath holds, typically 9 to 12, to cover the wholeTa
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December 5, 2006:2324–39 Year in Cardiac Imagingeart. Several investigators studied a faster process. Narayan
t al. (80) developed a rapid ungated imaging sequence
hich allowed for coverage of the heart in a single breath
old. They tested it on 20 patients and compared it with the
raditional gated cardiac sequence. They found the 2 meth-
ds to be very comparable, as shown by the narrow 95%
onfidence intervals for the mean difference between the
apid and conventional measurements of LVEF (1.1% to
%) and RVEF (7.2% to 1.3%). Taylor et al. (81)
eveloped a similar non-breath hold method, which they
ested in 28 patients with congenital heart disease. The 95%
onfidence intervals as calculated from their data were also
ery small (LVEF: 4.4% to 0.4%; RVEF: 3.9% to
.5%).
TEM CELL THERAPY
rials. There is great interest in using stem cells for
reating damaged myocardium. Most trials of this therapy
ave used imaging end points, especially MRI volume
easurements and infarct sizes. Two main types of treat-
ent have been studied in patients with acute STEMI. In
ne line of study, granulocyte colony-stimulating factor, a
ytokine that stimulates the bone marrow to produce
able 4. MRI Volume Measurements in 108 Normal Volunteers
Intraobserver
Mean Difference
(95% Limits of Agreement)
V ejection fraction 0.5 (2.6 to 3.5)
V end-diastolic volume index 4.6 (4.4 to 13.7)
V mass 5.4 (6.8 to 17.5)
V ejection fraction 0.1 (6.2 to 6.4)
V end-diastolic volume index 3.2 (18.8 to 12.5)
A ejection fraction 1 (18 to 17)
nterstudy reproducibility was measured in only 12 of the 108 volunteers. Data from
LA  left atrium; LV  left ventricular; RV  right ventricular.
able 5. Human Granulocyte Colony-Stimulating Factor (G-CS
Author Design Rx Pl Co Delivery
ipa et al. (82) RT 39 39 — SubQ
ohlnhofer
et al. (83)
RT 56 58 — SubQ
algimigli
et al. (84)
RT 10 10 — SubQ
nce et al. (85) RT 15 — 15 SubQ
uethe
et al. (86)
MC 14 — 9 subQ
ath cardiac catheterization; Co control; Echo echocardiography; LVEF lef
yocardial scintigraphy; MUGA  technetium 99m-labeled red blood cell multi-gated ac
s in Tables 1 and 4.eutrophil precursor cells, was injected subcutaneously. In
he other line of study, stem cells were harvested from a
atient and then reinjected, typically directly into the
oronary arteries. The results of the studies (82–93) are
abulated in Tables 5 and 6. A similar smaller literature
xists for stem cell therapy of chronic infarction (94).
The results of these small studies are generally mixed.
he imaging end points used in these studies measure
ffects on ventricular function, apparent infarct size, and
estenosis. Although these end points are clinically mean-
ngful, they do not offer any insight into the fate of the
njected or mobilized cells, which has stimulated interest in
he direct imaging of stem cells.
irect imaging. MRI. Studies in which stem cells have
een tracked to the myocardium (95–99) are summarized in
able 7. The discovery that stem cells can phagocytize
ommercially available iron particles, which are detectable
y MRI, has led to recent heightened interest in MRI for
irectly imaging stem cells. Although MRI has better
patial resolution than SPECT or PET, MRI imaging of
tem cells has 2 major limitations compared with nuclear
ethods. First, the signal detected by MRI is not propor-
ional to the iron load, so that it is very difficult to use MRI
Interobserver Interstudy
Mean Difference
(95% Limits of Agreement)
Mean Difference
(95% Limits of Agreement)
1.6 (2.8 to 6.0) 0.5 (9.1 to 10.1)
0.4 (3.8 to 4.6) 1.4 (9.7 to 6.9)
5.8 (4.4 to 16.0) 1.8 (17.9 to 21.6)
2.8 (15.2 to 9.1) 1.9 (11.48 to 15.2)
0.1 (16.7 to 16.5) 0.7 (21 to 4.3)
4.4 (6 to 15) 3 (19 to 12)
mith et al. (78).
rials in Acute ST-Segment Elevation Myocardial Infarction
ary Outcome Variables Result
nal thickening (MRI)* No differences between groups.
F (MRI and echo)
olumes (MRI and echo)
ct size (MRI)
F (MRI) No differences between groups.
ct size (MIBI)
nosis (cath)
F (MIBI) No differences between groups.
ct size (MIBI)
nosis (cath) Improved wall thickening (p  0.05) and
EF (p  0.005) in treated groups.F (echo)
nal wall motion (echo)
ct size (MIBI) Infarct size (p  0.05) and wall motion
(p  0.01) improved more in treated
than control. LVEF significantly
increased in both groups, with no
difference between groups.
F (MUGA)
all motion (MIBI)
icular ejection fraction; MCmatched controls; MIBI technetium 99m sestamibiF) T
Prim
Regio
LVE
LV v
Infar
LVE
Infar
Reste
LVE
Infar
Reste
LVE
Regio
Infar
LVE
LV w
t ventr
quisition; Pl  placebo; RT  randomized trials; Rx  treated; other abbreviations
Table 6. Human Stem Cell Trials in Acute ST-Segment Elevation Myocardial Infarction
Author (Ref.) Design
n
Treatment Delivery Primary End Point ResultsRx Pl Co
Janssens et al. (87) RT 33 34 — BMSC Intracoronary
injection
LVEF (MRI)
Wall thickening (MRI)
Infarct size (MRI)
Metabolism (PET)
Perfusion (PET)
Greater decrease in infarct size (p  0.036) in
treated group. No other difference between
groups.
Ruan et al. (88) RT 9 11 — BMSC Intracoronary LVEF (echo)
LV strain (echo)
Improvement in strain parameters in treatment
group (p  0.001), but not control, LVEF
higher in treated than control group after 6
months (p  0.05).
Bartunek et al. (89) MC 19 — 16 CD133 BMSC Intracoronary Infarct size (MIBI)
Infarct metabolism (PET)
LVEF (cath)
LVEF, infarct size, metabolism in infarct
improved in treated group (p  0.05), not
control. Higher incidence in coronary events
at 4 months in treated group.
Wollert/Meyer
et al. (90,91)
RT 30 30 30 BMSC Intracoronary LVEF (MRI)
Infarct size (MRI)
LVEF significantly increased at 6 months in
treated group compared to controls (p 
0.0026). No difference in infarct size. After
18 months difference in LVEF
improvement less pronounced and no longer
significant (p  0.27).
Chen et al. (92) RT 34 35 — BMSC Intracoronary Infarct size (MIBI)
LVEF (echo)
Smaller infarct size and higher LVEF in
treatment group than control at 3 months
(p  0.05).
Schachinger
et al. (93)
RT 30 CPC
29 BMC
— — CPC, BMC Intracoronary LVEF (cath, MRI)
Infarct size (MRI)
Increase in LVEF and decrease in infarct size,
but no difference between cell groups.
Several of these studies were published in 2004.
BMSC  bone marrow derived stem cell; CPC  circulating progenitor cells; G-CSF  granulocyte colony-stimulating factor; other abbreviations as in Table 5.
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Table 7. Direct Myocardial Imaging of Labeled Stem Cells
Author
(Ref.) Model n
Disease
Model Cell Delivery Dose Label
Imaging
Method Results
Histologic
Confirmation?
Arai et al.
(95)
Mouse 21 total (4 with
non-labeled
cells, 3 with
labeled cells)
Acute MI ES DM 2.5  105 Iron (Feridex-
PLL)
MRI 1.5 T Focal area of signal loss at site
of labeled cell injection.
Yes
Kraitchman
et al. (96)
Canine 6 Acute MI MSC IV 1.6  108 Iron (Feridex-
PLL)
In111Oxime
MRI 1.5 T
SPECT/CT
SPECT/CT uptake in
infarcted myocardium, liver,
kidney, spleen by 24–48 h,
no MRI detectable uptake.
Yes
Kustermann
et al. (97)
Mouse 21 (8 with infarct
and no cells, 5
normal animals
with cells, 8
infarct animals
with cells)
Acute MI Embryonic
ventricular
cardiomyocites
DM 10  104 Iron (USPIO) MRI 7 T Focal area of signal loss at site
of labeled cell injection.
Yes
Hofmann
et al. (98)
Human 9 patients (3 with
unselected
BMCs injected
intracoronary,
3 with
unselected
BMCs injected
IV and then
intracoronary,
3 with CD34
enriched
BMCs injected
intracoronary)
Acute MI BMC, CD34
enriched
BMC
IC and/
or IV
Unclear
1.3  106
to
45.5  108
F18-FDG PET After intracoronary injection of
unselected BMCs less than
3% was in the myocardium,
the remainder was in the
liver and spleen. IV infusion
produced no significant
myocardial activity.
Intracoronary injection of
CD34 enriched cells
showed 14–39% of total
activity in the myocardium.
No
Cao et al.
(99)
Rat 26 total (20 with
labeled cells, 6
with unlabeled
cells)
None ES DM 1  107 F18-FHBG MicroPET
Bioluminescence
Repeated imaging over
4 weeks showed good
correlation between
MicroPET,
bioluminescence, and ex-vivo
assays for detection of ES
cells.
Yes
BMC  bone marrow cells; DM  direct myocardial; ES  embryonic stem cells; F18-FDG  F18 fluorodeoxyglucose; F18-FHBG  9-(4-F18-fluoro-3hydroxymethylbutyl)guanine; IC  intracoronary; IV  intravenous; MSC 
mesenchymal stem cells; PET  positron emission tomography; PLL  poly L lysine; SPECT  single-photon emission computerized tomography; USPIO  ultrasmall superparamagnetic iron oxide; other abbreviations as in Tables
1 and 3.
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Year in Cardiac Imaging December 5, 2006:2324–39o quantitate cell concentration. Second, MRI requires
uch higher concentrations of cells to generate any mea-
urable signal, so that direct percutaneous injection of the
ells into the site of interest is usually required. This is well
emonstrated in the study by Kraitchman et al. (96), in
hich intravenously injected cells were detectable by
PECT and not by MRI.
PPROPRIATENESS
atel et al. (100) published a methodologic paper describing
he modified RAND/UCLA approach taken by the Amer-
can College of Cardiology Foundation (ACCF) in the
evelopment of appropriateness criteria for cardiovascular
maging. In a companion paper, Brindis et al. (101) de-
cribed ACCF/American Society of Nuclear Cardiology
ppropriateness criteria for SPECT myocardial perfusion
maging in 52 separate patient situations. Both are currently
nder review by third-party payers.
Two separate papers described recent North American
rends in the use of diagnostic testing. Lucas et al. (102)
ublished a cross-sectional population-based study of Medi-
are patients from 1993 to 2001. They demonstrated a 6%
verage annual increase in imaging stress tests, which far
xceeded the annual increase in either percutaneous coro-
ary intervention or cardiac catheterization. The annual
ncrease in non-black men (7.8%) exceeded the annual
ncrease in non-black women, black men, or black women
all 5.4% to 5.7%). Alter et al. (103) published a similar
nalysis of the residents of Ontario, Canada. Between 1992
nd 2001, the annual increase in perfusion imaging in
atients 65 years old was a robust 10%, although the rates
f imaging were only about one-third of the rates reported
n the U.S. In an accompanying editorial, Ayanian et al.
104) argued strongly for physician responsibility to ensure
hat cardiac procedures are used effectively and efficiently.
In a separate analysis of Medicare data from 1998 to
002, Levin et al. (105) reported that SPECT myocardial
erfusion imaging increased by 42% from 1998 to 2002.
he increase in use was greater for cardiologists (78%) than
or radiologists (2%). The increase for cardiologists was
reater than the increase in coronary angiography (19%) or
tress echocardiography (21%) among cardiologists.
The American Heart Association issued a scientific
dvisory calling for more scientific research to critically
xamine emerging imaging modalities such as MRI and CT
s well as the development of rigorous appropriateness
riteria for all imaging techniques (106). Schoenhagen et al.
107) echoed this appeal for more evaluation and validation
f emerging cardiac imaging tests, specifically cardiac CT,
nd advocated a multidisciplinary approach to establish
ppropriate guidelines for education and utilization.OLECULAR IMAGING
he enormous emerging literature in this field is beyond the
cope of this article. In addition to the studies listed in Table
for stem cells, 2 other SPECT studies were noteworthy.
Su et al. (108) reported on the use of an indium-111–
abeled matrix metalloproteinase–targeted radiotracer in a
ouse model of acute MI. They demonstrated a 5-fold
ncrease in myocardial uptake in the infarct region and a
esser increase in remote regions. This novel radiotracer has
otential for in vivo localization and tracking of matrix
etalloproteinase activity.
Hua et al. (109) demonstrated the potential value of a
echnetium-99m–labeled peptide targeted at alphav beta3
ntegrin in the identification of angiogenesis distal to
emoral occlusion in a mouse model. This radiotracer has
otential value in tracking therapeutic myocardial angio-
enesis.
ONCLUSIONS
he authors hope that this review will stimulate the reader
o examine at least a few of these current original articles on
ardiac imaging in detail. If so, we will have achieved our
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